Modality
Gene Editing
MOA
ALKi
Target
PD-L1
Pathway
STING
CF
Development Pipeline
Preclinical
~Aug 2016
→ ~Nov 2017
Phase 1
Feb 2018
→ Jan 2030
Phase 1Current
NCT04654698
2,720 pts·CF
2022-05→2030-01·Completed
NCT04425418
272 pts·CF
2018-02→2028-06·Recruiting
2,992 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-072.2y awayInterim· CF
2030-01-163.8y awayInterim· CF
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P1
Recruit…
P1
Complet…
Catalysts
Interim
2028-06-07 · 2.2y away
CF
Interim
2030-01-16 · 3.8y away
CF
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04654698 | Phase 1 | CF | Completed | 2720 | HAM-D |
| NCT04425418 | Phase 1 | CF | Recruiting | 272 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA |